TWI426897B - Barrier for capsule, capsule using the same, and method of filling capsule - Google Patents

Barrier for capsule, capsule using the same, and method of filling capsule Download PDF

Info

Publication number
TWI426897B
TWI426897B TW99144189A TW99144189A TWI426897B TW I426897 B TWI426897 B TW I426897B TW 99144189 A TW99144189 A TW 99144189A TW 99144189 A TW99144189 A TW 99144189A TW I426897 B TWI426897 B TW I426897B
Authority
TW
Taiwan
Prior art keywords
capsule
barrier layer
homogeneous substance
filling
homogeneous
Prior art date
Application number
TW99144189A
Other languages
Chinese (zh)
Other versions
TW201121538A (en
Inventor
Ikuo Goto
Chin-Chih Chiang
Remy Chen
Original Assignee
Orient Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orient Pharma Co Ltd filed Critical Orient Pharma Co Ltd
Priority to TW99144189A priority Critical patent/TWI426897B/en
Publication of TW201121538A publication Critical patent/TW201121538A/en
Application granted granted Critical
Publication of TWI426897B publication Critical patent/TWI426897B/en

Links

Description

用於膠囊中之阻隔層、使用其之膠囊、以及膠囊充填方法Barrier layer for use in capsule, capsule using same, and capsule filling method

本發明係關於一種利用膠囊之充填裝置將多種均質物充填於膠囊內的方法。The present invention relates to a method of filling a plurality of homogeneous substances into a capsule using a filling device for a capsule.

圖1A係為周知的一般膠囊之形狀,該膠囊係由筒狀本體與筒狀蓋體所構成,本體外形係比蓋體外形小,但亦可以外形較大的筒狀蓋體來定義本體。圖1A中係以外形較小者來定義本體。在上述膠囊裝入充填物的過程中,蓋體與本體暫時結合的空膠囊會先於進料斗(hopper)內,再從進料斗逐次釋出固定個數,並使蓋體從本體分離。在本體裝入藥後,再結合蓋體使其不脫離本體。依情況,例如可依防臭、防漏、防氧穿透等目的,使蓋體與本體上漿密封之後進行乾燥作業。Fig. 1A is a shape of a generally known capsule which is composed of a cylindrical body and a cylindrical lid body. The outer shape of the body is smaller than the outer shape of the lid body, but the body can be defined by a cylindrical lid body having a large outer shape. In Figure 1A, the body is defined by a smaller profile. During the loading of the capsule into the filling, the empty capsule temporarily combined with the body will precede the hopper, and the fixed number will be released from the feeding hopper and the cover will be separated from the body. After the body is loaded with the drug, the cover is combined with the cover so as not to be separated from the body. Depending on the situation, for example, the lid body and the body may be sizing and sealed for drying purposes according to the purpose of deodorization, leakage prevention, and oxygen penetration prevention.

市場上存在各種在膠囊中充填藥物或其他物質的裝置,能進行如上述之膠囊充填。當充填物為一種之粉狀固體或顆粒時問題較少,但是在充填半固體或液體時,尤其是在充填具有藥性之二種半固體或液體時,為了維護預期藥效而有如下問題。亦即,最先充填的半固體或液體形態充填物之上部界面需為水平且平穩,且不會與下一個步驟中充填的半固體或液體相混合,如相混合就會發生因藥物相互作用而無法獲得預期藥效的問題。There are various devices on the market for filling drugs or other substances in capsules, and capsule filling as described above can be performed. There are fewer problems when the filling is a powdery solid or granule, but when filling a semi-solid or liquid, especially when filling two semi-solids or liquids having medicinal properties, the following problems are solved in order to maintain the intended efficacy. That is, the upper interface of the first filled semi-solid or liquid form filling should be horizontal and stable, and will not mix with the semi-solid or liquid filled in the next step. If mixed, drug interaction will occur. The problem of expected efficacy is not available.

另一方面,一旦所充填的半固體或液體之表面起泡,或非為固定形狀,就會發生例如:在界面接近水平與相對於水平呈較大傾斜時,以及界面平滑與相對平滑而表面起泡時,藥物表面之面積起較大變化,且在藥物溶析所花的時間亦發生變化而無法獲得預期藥效的問題。On the other hand, once the surface of the filled semi-solid or liquid is foamed, or not in a fixed shape, for example, when the interface is close to horizontal and is inclined with respect to the horizontal, and the interface is smooth and relatively smooth, the surface At the time of foaming, the area of the surface of the drug changes greatly, and the time taken for the dissolution of the drug also changes to obtain the problem of the intended drug effect.

為解決上述問題,本發明提供一種防止所充填的藥物相混合或/及作用之多層填充膠囊及其製造方法。In order to solve the above problems, the present invention provides a multilayer filled capsule which prevents mixing or/and action of a filled drug and a method of manufacturing the same.

本發明之一目的在於提供一種多層填充膠囊及其製造方法,可形成含有不同溶析特性之相同藥物的膠囊。It is an object of the present invention to provide a multilayer filled capsule and a method of producing the same that can form a capsule containing the same drug having different elution characteristics.

本發明之一目的在於提供一種多層填充膠囊及其製造方法,可防止所充填的藥物發生溶析特性的變化。An object of the present invention is to provide a multilayer filled capsule and a method for producing the same, which can prevent a change in the elution characteristics of a filled drug.

本發明之另一目的在於提供一種多層填充膠囊及其製造方法,可形成含有不同藥物的膠囊。Another object of the present invention is to provide a multilayer filled capsule and a method of manufacturing the same that can form a capsule containing different drugs.

本發明之另一目的在於提供一種多層填充膠囊及其製造方法,可防止所充填之藥物的相互作用。Another object of the present invention is to provide a multilayer filled capsule and a method of manufacturing the same that prevent interaction of the filled drug.

本發明提供一種多層填充膠囊。多層填充膠囊包含本體與至少一蓋體,其中本體具有至少一開口及內部空間,而蓋體則可分離地與本體結合以封閉開口;再者,本體另包含與環繞內部空間之內壁連接之阻隔層。阻隔層由安定性之成份組成且將內部空間分隔為第一分隔空間及第二分隔空間;第一分隔空間及第二分隔空間並且分別具有第一均質物及第二均質物。即膠囊本體之內部空間將形成有三個充填單元/充填層。此外,第一均質物及第二均質物二者在常溫及貯存條件下之形態可以是液體、固體、或半固體,其中液體包括均質液體及懸浮液;固體包括固體塊、微膠囊、顆粒、或粉狀固體例如粉末。固體塊之特性係在其熔點溫度以上具有液體形態或半固體形態。The present invention provides a multilayer filled capsule. The multi-layer filling capsule comprises a body and at least one cover body, wherein the body has at least one opening and an inner space, and the cover body is detachably coupled with the body to close the opening; further, the body further comprises a connection with the inner wall surrounding the inner space. Barrier layer. The barrier layer is composed of a stable component and partitions the internal space into a first partition space and a second partition space; the first partition space and the second partition space and respectively have a first homogeneous substance and a second homogeneous substance. That is, the inner space of the capsule body will be formed with three filling units/filling layers. In addition, the first homogeneous substance and the second homogeneous substance may be in the form of a liquid, a solid or a semi-solid under normal temperature and storage conditions, wherein the liquid comprises a homogeneous liquid and a suspension; the solid comprises a solid block, a microcapsule, a pellet, Or a powdery solid such as a powder. The characteristics of a solid block have a liquid form or a semi-solid form above its melting point temperature.

本發明多層填充膠囊的製造方法包含下列步驟:膠囊以蓋體與本體結合的狀態收容於進料斗內;將由進料斗取出的膠囊進行方向限制,使本體的開口水平朝上;將膠囊之蓋體從本體分離,使得膠囊上端為開口;排除分離不良之膠囊以及本體有缺陷之膠囊,以便進行填充;以及填充第一均質物,其包含加熱第一均質使其為具流動性的液體或半固體形態而便於充填;冷卻第一均質物,其包含使充填時具流動性的第一均質物固化;充填阻隔層,包含決定阻隔層組成份礦物油及石蠟的比例來設定阻隔層之適當熔點,並加熱阻隔層組成份使其具流動性而便於充填,並且加熱後之阻隔層溫度不致使前一步驟固化的第一均質物回融;冷卻阻隔層,使其固化;充填第二均質物,其包含加熱第二均質物使其為具流動性的液體或半固體形態而便於充填,並且加熱後之第二均質物溫度不致使前一步驟固化的阻隔層回融;冷卻第二均質物,其包含使充填時具流動性的第二均質物固化;蓋體與本體結合,完成膠囊製造;以及最後排出膠囊並排除不填充或填充不完全之膠囊及清潔。除此之外,亦可於膠囊內部空間形成與內壁連接之阻隔層,而先將內部空間分隔為不含充填物的第一分隔空間及第二分隔空間,然後再分別於第一分隔空間及第二分隔空間充填第一均質物及第二均質物。The method for manufacturing a multi-layered filled capsule of the present invention comprises the steps of: the capsule is housed in the feeding hopper in a state in which the lid body is combined with the body; the capsule taken out from the feeding hopper is directionally restricted so that the opening of the body is horizontally upward; Separating from the body such that the upper end of the capsule is open; removing the poorly-separated capsule and the body-deficient capsule for filling; and filling the first homogeneous substance, comprising heating the first homogenate to make it a fluid or semi-solid Forming to facilitate filling; cooling the first homogeneous substance, comprising curing the first homogeneous substance having fluidity during filling; filling the barrier layer, comprising determining a proportion of the barrier layer component mineral oil and paraffin wax to set an appropriate melting point of the barrier layer, And heating the barrier layer component to make it fluid and convenient for filling, and the temperature of the barrier layer after heating does not cause the first homogeneous substance solidified in the previous step to remelt; cooling the barrier layer to solidify; filling the second homogeneous substance, It comprises heating the second homogenate to make it a liquid or semi-solid form with fluidity for easy filling and heating The homogenate temperature does not cause the barrier layer to be cured in the previous step to remelt; the second homogenate is cooled, which comprises solidifying the second homogenate with fluidity during filling; the lid body is combined with the body to complete the capsule manufacturing; and finally the capsule is discharged And exclude capsules that are not filled or incompletely filled and cleaned. In addition, a barrier layer connected to the inner wall may be formed in the inner space of the capsule, and the inner space is first divided into a first separation space and a second separation space without a filling, and then respectively in the first separation space. And the second partition space is filled with the first homogeneous substance and the second homogeneous substance.

本發明提供一種多層填充膠囊,其填充有不同溶析特性之相同藥物或不同藥物。為了膠囊內藥物貯存時之穩定並獲得預期藥效,以及為確保藥物在填充過程中不相互影響,本發明之多層填充膠囊包含了在製造膠囊的過程中充填以安定性成份調製而成之阻隔層。詳細來說,如圖1A-1B所示,本發明之膠囊1包含本體2與至少一蓋體3;其中本體具有至少一開口4及內部空間5,而蓋體3則較佳具有較本體2大之口徑以可分離地與本體2結合以封閉開口4;再者,本體2另包含環繞內部空間之內壁,阻隔層即與內壁連接並將內部空間分隔為第一分隔空間及第二分隔空間(未示於圖)。其中阻隔層之厚度較佳佔該本體總長的5%至25%。阻隔層材料係採用對生物無害之安定性成份。當阻隔層隨膠囊進入消化道之後,消化道環境並可將以該些成份調製形成的阻隔層熔解、分解、或直接排出。在本發明較佳實施例中,阻隔層組成份為礦物油及/或石蠟,其中礦物油與石蠟成份之重量比值介於0至4之間,亦即阻隔層組組成份中的礦物油含量最少可以是0;換句話說,阻隔層組成份必包含石蠟,以使阻隔層在常溫或膠囊貯存條件下具固體形態。礦物油與石蠟之比例影響阻隔層熔點的高低,其與膠囊製造方法的關係,將於後詳述。The present invention provides a multilayer filled capsule filled with the same drug or different drugs having different elution characteristics. In order to stabilize the drug during storage of the capsule and obtain the expected drug effect, and to ensure that the drug does not interact with each other during the filling process, the multi-layered filled capsule of the present invention comprises a barrier which is prepared by the stability component during the process of manufacturing the capsule. Floor. In detail, as shown in FIGS. 1A-1B, the capsule 1 of the present invention comprises a body 2 and at least one cover 3; wherein the body has at least one opening 4 and an internal space 5, and the cover 3 preferably has a body 2 The large diameter is detachably combined with the body 2 to close the opening 4; further, the body 2 further comprises an inner wall surrounding the inner space, the barrier layer is connected to the inner wall and divides the inner space into the first separation space and the second Separation space (not shown). The thickness of the barrier layer preferably ranges from 5% to 25% of the total length of the body. The barrier layer material is a non-hazardous ingredient that is biologically innocuous. After the barrier layer enters the digestive tract with the capsule, the digestive tract environment can melt, decompose, or directly vent the barrier layer formed by the modulation of the components. In a preferred embodiment of the present invention, the barrier layer component is mineral oil and/or paraffin wax, wherein the weight ratio of the mineral oil to the paraffin component is between 0 and 4, that is, the mineral oil content in the barrier layer component. It may be at least 0; in other words, the barrier layer component must contain paraffin wax so that the barrier layer has a solid form under normal temperature or capsule storage conditions. The ratio of mineral oil to paraffin affects the melting point of the barrier layer, and its relationship with the capsule manufacturing method will be described in detail later.

如圖4所示,第一分隔空間61及第二分隔空間62分別容納有第一均質物51及第二均質物52,亦即阻隔層50分隔第一均質物51及第二均質物52;換言之,膠囊本體之內部空間具有三個充填單元/充填層。在較佳實施例中,第一均質物及第二均質物為藥物。第一均質物或第二均質物在常溫及貯存條件下之形態可以是液體、固體、或半固體,其中液體包括均質液體及懸浮液;固體包括固體塊、微膠囊、顆粒、或粉狀固體例如粉末;半固體係為具黏性之流體,且其流動力與同為流體之液體相較下較為緩慢。固體塊之特性係在高於常溫、且較佳在高於35℃的溫度條件下為液體形態或半固體形態。當第一均質物或第二均質物在常溫下及貯存條件下之形態為固體塊時,第一均質物或第二均質物的成份進一步包含在高於常溫、且較佳在高於35℃的溫度條件下為液體形態或半固體形態之熱熔性賦形劑;其中第一均質物之熔點大於阻隔層之熔點,而阻隔層之熔點大於第二均質物之熔點。As shown in FIG. 4, the first partitioning space 61 and the second partitioning space 62 respectively accommodate the first homogeneous substance 51 and the second homogeneous substance 52, that is, the barrier layer 50 separates the first homogeneous substance 51 and the second homogeneous substance 52; In other words, the inner space of the capsule body has three filling units/filling layers. In a preferred embodiment, the first homogeneous substance and the second homogeneous substance are drugs. The first homogeneous substance or the second homogeneous substance may be in the form of a liquid, a solid or a semi-solid under normal temperature and storage conditions, wherein the liquid comprises a homogeneous liquid and a suspension; the solid comprises a solid block, a microcapsule, a granule, or a powdery solid. For example, a powder; a semi-solid is a viscous fluid, and its flow force is slower than that of a fluid that is also a fluid. The solid block is characterized by a liquid form or a semi-solid form at a temperature above normal temperature, and preferably above 35 °C. When the first homogeneous substance or the second homogeneous substance is in the form of a solid block at normal temperature and under storage conditions, the composition of the first homogeneous substance or the second homogeneous substance is further included at a temperature higher than normal temperature, and preferably higher than 35 ° C. a hot-melt excipient in a liquid form or a semi-solid form under temperature conditions; wherein the melting point of the first homogeneous substance is greater than the melting point of the barrier layer, and the melting point of the barrier layer is greater than the melting point of the second homogeneous substance.

本發明同時包含了製造多層填充膠囊的充填方法,其中多層填充膠囊的充填係由膠囊充填裝置完成,該充填裝置可以間歇驅動方式及/或連續驅動方式完成膠囊充填/製造,且適用於圓盤方式、鏈結(chain link)方式中之膠囊支架。請同時參考圖2所示之實施例流程圖及圖3-4之示意圖,步驟810包含:膠囊以蓋體與本體結合的狀態收容於進料斗內。步驟820包含:將由進料斗取出的膠囊進行方向限制。為了使所充填之第一均質物、阻隔層及第二均質物具有固定形狀,並且與相鄰填充物具有較小接觸面以確保藥物溶析效果,因此在步驟820中,膠囊1之方向限制較佳為如圖4所示,即本體2與蓋體3之軸心垂直於水平面,而開口水平朝上;如此一來,充填物之界面在最佳狀態下會與開口平行,且相鄰充填物間會有最小接觸面或最小表面。其中,膠囊的方向限制係可由感應裝置例如雷射感測器達成,例如雷射感測器可測得膠囊為正向或反向,若膠囊為反向,則膠囊在通過方向校正盤時會反轉為正向,若膠囊為正向,則膠囊在通過方向校正盤時不會有任何動作。步驟830包含:將膠囊之蓋體從本體分離,使得膠囊上端為開口。接著,步驟840為排除分離不良之膠囊以及本體有缺陷之膠囊。其中,在正常的機器動作中,膠囊在步驟830會分離成蓋體與本體,但若膠囊分離不良,無法在此步驟分離,則在步驟840中,未分離的膠囊會藉由機械性的動作由一頂針頂出至不良膠囊的收集盒;另一種情況為膠囊為只剩下本體或只剩下蓋體的缺陷膠囊,此類膠囊係由兩個雷射感應器測得:其中一感應器係用以偵測膠囊本體,另一個係用以偵測膠囊蓋體,兩感應器需同時偵測到膠囊的蓋體與本體,機器才會進行下一步驟(即步驟850);當二個感應器中只有一個偵測到膠囊時,則機器會停止,直到以人工排除缺陷膠囊之後才可繼續運作機器。The invention also comprises a filling method for manufacturing a multi-layer filling capsule, wherein the filling of the multi-layer filling capsule is completed by a capsule filling device, which can complete the capsule filling/manufacturing in an intermittent driving manner and/or a continuous driving manner, and is suitable for the disc Capsule holder in the way, chain link mode. Please refer to the flow chart of the embodiment shown in FIG. 2 and the schematic diagram of FIG. 3-4. Step 810 includes: the capsule is received in the feeding hopper in a state in which the cover body and the body are combined. Step 820 includes directionalally limiting the capsules removed from the hopper. In order to have the first homogenate, the barrier layer and the second homogeneous substance filled have a fixed shape and have a small contact surface with adjacent fillers to ensure a drug elution effect, in step 820, the direction of the capsule 1 is limited. Preferably, as shown in FIG. 4, the axis of the body 2 and the cover 3 is perpendicular to the horizontal plane, and the opening is horizontally upward; thus, the interface of the filler is optimally parallel to the opening and adjacent to each other. There will be minimal contact or minimum surface between the fillings. Wherein, the direction limitation of the capsule can be achieved by an inductive device such as a laser sensor, for example, the laser sensor can measure the positive or negative direction of the capsule, and if the capsule is reversed, the capsule will correct the disk when passing the direction. Reverse to positive, if the capsule is positive, the capsule will not have any action when correcting the disc through the direction. Step 830 includes separating the lid of the capsule from the body such that the upper end of the capsule is open. Next, step 840 is to exclude the capsule with poor separation and the capsule with defective body. In the normal machine operation, the capsule is separated into a cover body and a body in step 830. However, if the capsule is poorly separated and cannot be separated in this step, in step 840, the unseparated capsule will be mechanically actuated. The ejector pin is ejected to the collection box of the defective capsule; in the other case, the capsule is a defective capsule with only the body remaining or only the cover remaining, and the capsule is measured by two laser sensors: one of the sensors It is used to detect the capsule body, and the other is used to detect the capsule cover. The two sensors need to detect the cover and the body of the capsule at the same time, and the machine will proceed to the next step (ie, step 850); When only one of the sensors detects a capsule, the machine will stop until the defective capsule is manually removed before continuing to operate the machine.

步驟850包含:充填第一均質物。其中,第一均質物51較佳在高於常溫、且較佳高於35℃之條件下具有液體或半固體形態,而在低於35℃、或者在溫度至少降低至常溫時為固體塊,以避免充填下一層充填物(即,阻隔層)時發生混合;其中加熱第一均質物使之為液體或半固體形態的目的即藉著液體及半固體之流動性來將第一均質物充填至膠囊中。舉例來說,若第一均質物具有熔點A℃,且在至少冷卻至a℃時表面能固化為固體塊,則步驟850進一步包含充填溫度A℃以上的第一均質物51,此時第一均質物51具有流動性而易於進行充填。步驟855包含:冷卻第一均質物。承接步驟850之例,亦即使得充填時溫度A℃以上的第一均質物51溫度降低至a℃以下。冷卻方式包含但不限於將空氣或冷風吹進膠囊本體、膠囊本體支架或是所充填的液體或半固體形態之第一均質物51而使之冷卻並加快固化速度。此外,亦可設置外部冷卻裝置,例如:利用冷煤使膠囊支架直接冷卻,使其上之膠囊本體及第一均質物51冷卻。另一方面,若第一均質物51不需經加熱再行充填,亦即/或者是在充填時與常溫及/或貯存條件下時有相同形態,例如充填時為顆粒狀、且膠囊形成後即以顆粒狀容納於膠囊中時,則可不進行步驟855。完成步驟850~855即形成第一充填單元/充填層。Step 850 includes filling the first homogeneous mass. Wherein, the first homogeneous substance 51 preferably has a liquid or semi-solid form at a temperature higher than normal temperature, and preferably higher than 35 ° C, and is a solid block at a temperature lower than 35 ° C or at least when the temperature is lowered to a normal temperature. To avoid mixing when filling the next layer of filling (ie, barrier layer); wherein the first homogeneous substance is filled by the liquid and semi-solid flow by heating the first homogeneous substance to a liquid or semi-solid form Into the capsule. For example, if the first homogeneous substance has a melting point of A ° C and the surface can be solidified into a solid block when cooled to at least A ° C, the step 850 further includes a first homogeneous substance 51 having a filling temperature of A ° C or higher, at this time, The homogeneous substance 51 has fluidity and is easy to be filled. Step 855 includes cooling the first homogeneous mass. In the example of step 850, the temperature of the first homogeneous substance 51 above the temperature A °C at the time of filling is lowered to below a °C. The cooling means includes, but is not limited to, blowing air or cold air into the capsule body, the capsule body holder or the first homogeneous substance 51 in a filled liquid or semi-solid form to cool and speed up the curing. In addition, an external cooling device may be provided, for example, the capsule holder is directly cooled by cold coal, and the capsule body and the first homogeneous substance 51 are cooled. On the other hand, if the first homogeneous substance 51 is not required to be filled by heating, that is, it is the same form when it is filled and under normal temperature and/or storage conditions, for example, it is granular when filled, and after the capsule is formed. That is, when it is contained in a capsule in a pellet form, step 855 may not be performed. Upon completion of steps 850-855, a first filling unit/filling layer is formed.

步驟860包含:充填阻隔層,並形成充填有第一均質物51的第一分隔空間61及尚未有充填物的第二分隔空間62。其中,阻隔層的使用量較佳為使阻隔層形成後具有佔本體總長5%至25%的厚度,但不以此為限。此外,充填時,阻隔層為具有流動性的液體或半固體形態以易於進行充填。如上所述,阻隔層組成份較佳為礦物油及/或石蠟,其中礦物油與石蠟成份之重量比值介於0至4之間。當阻隔層組成份包含100%石蠟,則此時的阻隔層有最高的熔點,即,熔點範圍在60~65℃之間;當含有100%石蠟組成份的阻隔層被加熱至60~65℃時,阻隔層將產生相變化而具有液體或半固體形態。隨著礦物油比例提高,阻隔層熔點則下降,於是使阻隔層為液體或半固體形態所需之溫度可低於60~65℃。因此,步驟860進一步包含決定阻隔層熔點及礦物油及/或石蠟使用的比例。再者,承上所述,阻隔層的目的在於分隔第一均質物51及第二均質物,並且在第一均質物51充填完成後進行填充。由於阻隔層較佳係於已固化為固體塊之第一均質物51表面上充填,並且充填時的阻隔層為液體或半固體形態,因此,阻隔層熔點B℃必須小於A℃以避免充填阻隔層時,阻隔層的溫度使表面已固化的第一均質物51再溶化。也就是說,阻隔層的熔點要低於第一均質物的熔點,並且依熔點範圍決定礦物油與石蠟組成份的比例;其中,B℃較佳須大於常溫及/或貯存溫度,以防止阻隔層在常溫及/或貯存條件下熔化而失去阻隔能力,或者與他層填充物混合。此外,在充填方式上,為防止因充填時例如充填機噴嘴吐出阻隔層所造成的壓力使之前充填的填充物之表面變得粗糙,因此本發明之膠囊製造方法及實施膠囊製造之膠囊充填裝置係使得來自噴嘴的吐出觸及於膠囊的內壁7,並使吐出壓力降低而進行充填作業。即,如圖5所示,充填阻隔層之方式較佳為噴灑阻隔層組成份於內壁7之一釋出點R,釋出點R與內部空間5所含第一均質物51頂部之間的距離d為2 mm至3 mm之間,且噴灑點S與釋出點R所連成之噴灑線(箭號L)與該內壁7徑向之間的夾角Θ範圍較佳為為10°與40°之間。Step 860 includes filling the barrier layer and forming a first separation space 61 filled with the first homogeneous substance 51 and a second separation space 62 not yet filled. The barrier layer is preferably used in a thickness of 5% to 25% of the total length of the body after the barrier layer is formed, but is not limited thereto. Further, at the time of filling, the barrier layer is in a liquid or semi-solid form having fluidity for easy filling. As mentioned above, the barrier layer component is preferably mineral oil and/or paraffin wax, wherein the weight ratio of mineral oil to paraffin component is between 0 and 4. When the barrier layer component comprises 100% paraffin wax, the barrier layer at this time has the highest melting point, that is, the melting point ranges from 60 to 65 ° C; when the barrier layer containing the 100% paraffin component is heated to 60 to 65 ° C At the time, the barrier layer will undergo a phase change with a liquid or semi-solid morphology. As the proportion of mineral oil increases, the melting point of the barrier layer decreases, so that the temperature required to bring the barrier layer into a liquid or semi-solid form can be less than 60 to 65 °C. Thus, step 860 further includes determining the melting point of the barrier layer and the proportion of mineral oil and/or paraffin used. Furthermore, as described above, the purpose of the barrier layer is to separate the first homogeneous substance 51 and the second homogeneous substance, and to fill after the first homogeneous substance 51 is filled. Since the barrier layer is preferably filled on the surface of the first homogeneous substance 51 which has been solidified into a solid block, and the barrier layer during filling is in a liquid or semi-solid form, the melting point B ° C of the barrier layer must be less than A ° C to avoid filling barrier. At the time of the layer, the temperature of the barrier layer re-dissolves the first homogeneous substance 51 whose surface has solidified. That is, the melting point of the barrier layer is lower than the melting point of the first homogeneous substance, and the ratio of the mineral oil to the paraffin component is determined according to the melting point range; wherein B°C is preferably greater than normal temperature and/or storage temperature to prevent barrier The layer melts under normal temperature and/or storage conditions to lose barrier properties or to be mixed with other layer fillers. Further, in the filling method, in order to prevent the surface of the previously filled filler from being roughened by the pressure caused by, for example, the filling of the barrier layer during the filling of the filling machine nozzle, the capsule manufacturing method of the present invention and the capsule filling device for performing the capsule manufacturing The discharge from the nozzle is caused to touch the inner wall 7 of the capsule, and the discharge pressure is lowered to perform the filling operation. That is, as shown in FIG. 5, the filling barrier layer is preferably formed by spraying a barrier layer component at a discharge point R of the inner wall 7, between the release point R and the top of the first homogeneous substance 51 contained in the inner space 5. The distance d is between 2 mm and 3 mm, and the angle between the spray line (arrow L) and the radial direction of the inner wall 7 of the spray point S and the release point R is preferably 10 Between ° and 40 °.

步驟865包含:冷卻阻隔層。冷卻的目地係使得阻隔層較佳具有固體形態,以避免流體狀的阻隔層容易在下一層(即,第二均質物)充填時與之發生混合。因此需使充填時溫度B℃以上的阻隔層溫度降低至b℃以下。其中阻隔層溫度在至少降至b℃以下時,其表面能固化為固體塊。冷卻方式如上所述,於此不再贅述。完成步驟860~865即形成第二充填單元/充填層。Step 865 includes cooling the barrier layer. The purpose of the cooling is such that the barrier layer preferably has a solid form to prevent the fluid-like barrier layer from easily mixing with the next layer (i.e., the second homogeneous material) when it is filled. Therefore, it is necessary to lower the temperature of the barrier layer at a temperature of B ° C or higher at the time of filling to below b ° C. When the temperature of the barrier layer is at least below b ° C, the surface can be solidified into a solid block. The cooling method is as described above, and will not be described herein. Upon completion of steps 860-865, a second filling unit/filling layer is formed.

步驟870包含:充填第二均質物。其中,可以(1)固體形態之第二均質物52,例如:微膠囊、顆粒、或粉狀固體,或是(2)液體、半固體形態之第二均質物進行填充。其中,充填時為液體或半固體形態的第二均質物52在常溫或貯存條件下可同樣具有液體或半固體形態(2a);或者第二均質物52僅在充填時是具流動性的液體或半固體形態而進行充填,然而在常溫或者貯存條件下則固化為固體塊(2b),亦即,此第二均質物52在高於常溫、且較佳高於35℃的條件下為液體或半固體形態。Step 870 includes filling a second homogeneous mass. Wherein, (1) a second homogeneous substance 52 in a solid form, for example, a microcapsule, a granule, or a powdery solid, or (2) a second homogeneous substance in a liquid or semi-solid form may be filled. Wherein, the second homogeneous substance 52 in a liquid or semi-solid form upon filling may have a liquid or semi-solid form (2a) under normal temperature or storage conditions; or the second homogeneous substance 52 is a liquid liquid only when filled. Filling in a semi-solid form, but solidifying into a solid block (2b) under normal temperature or storage conditions, that is, the second homogenate 52 is liquid at a temperature higher than normal temperature and preferably higher than 35 ° C. Or semi-solid form.

舉例來說,當第二均質物52屬於上述(2b)之情形,且其熔點為C℃,則步驟870進一步包含充填溫度C℃以上的第二均質物52;再者,由於第二均質物52較佳係於已固化為固體形態之阻隔層50表面上充填,因此,第二均質物52熔點C℃必須小於B℃以避免充填時,第二均質物52的溫度使表面已固化的阻隔層50再溶化。也就是說,第二均質物52的熔點要低於阻隔層50的熔點。此時,綜合步驟850、步驟860,及步驟870,則可得知A℃>B℃>C℃,即熔點較高者須先行充填。以充填札來普隆(Zaleplon)三層填充膠囊為例。三層填充之札來普隆為一種含有兩層含藥層,即第一均質物與第二均質物,與一層不含藥之阻隔層的劑型,其中阻隔層組成份為石蠟,而兩含藥層在常溫下皆為固體塊。其中第一均質物的充填溫度為75~80℃,達到此溫度可使此層流動性較佳而易於進行充填;阻隔層組成份選擇100%石蠟,其充填溫度約為60~65℃;第二均質物的充填溫度則為55~60℃。因此,總括來說,為使第一均質物、阻隔層、及第二均質物達熔點,步驟850、步驟860,及步驟870亦包含加熱第一均質物、阻隔層或第二均質物,且加熱溫度範圍介於常溫與80℃之間,即25℃~80℃。此外,充填方式如同前述,於此不再贅述。For example, when the second homogeneous substance 52 belongs to the above (2b) and its melting point is C ° C, the step 870 further includes a second homogeneous substance 52 having a filling temperature of C ° C or higher; and further, due to the second homogeneous substance Preferably, 52 is filled on the surface of the barrier layer 50 which has been solidified into a solid form. Therefore, the melting point C°C of the second homogeneous substance 52 must be less than B°C to avoid the temperature of the second homogeneous substance 52 from curing when the filling is completed. Layer 50 is remelted. That is, the melting point of the second homogeneous substance 52 is lower than the melting point of the barrier layer 50. At this time, by integrating step 850, step 860, and step 870, it can be known that A ° C > B ° C > C ° C, that is, the higher melting point must be filled first. Take the example of filling a three-layer filled capsule of Zaleplon. The three-layer filled zaleplon is a dosage form containing two layers of drug-containing layers, namely a first homogeneous substance and a second homogeneous substance, and a layer of a drug-free barrier layer, wherein the barrier layer component is paraffin, and the two layers The drug layer is a solid block at normal temperature. The filling temperature of the first homogeneous substance is 75-80 ° C, and the temperature is obtained to make the layer better and easy to fill; the composition of the barrier layer is 100% paraffin wax, and the filling temperature is about 60-65 ° C; The filling temperature of the two homogeneous substances is 55 to 60 °C. Therefore, in order to achieve the melting point of the first homogeneous substance, the barrier layer, and the second homogeneous substance, the step 850, the step 860, and the step 870 also include heating the first homogeneous substance, the barrier layer or the second homogeneous substance, and The heating temperature range is between normal temperature and 80 ° C, that is, 25 ° C to 80 ° C. In addition, the filling method is the same as the foregoing, and will not be described herein.

步驟870之後選擇性地進行步驟875:冷卻第二均質物。較佳係將第二均質物52冷卻至常溫或適當貯存溫度。完成步驟870~875即形成第三充填單元/充填層。步驟880包含:結合蓋體與本體,完成具三個充填單元/充填層之膠囊的製造。步驟890包含:排出膠囊並排除不填充或填充不完全之膠囊。亦即,歷經步驟880之膠囊,係在步驟890中進入檢測裝置例如重量檢測裝置,當膠囊的重量未在規格之內,則該膠囊會自動被排除;而以此來區分填充完全、不填充或填充不完全之膠囊,並將後兩者排出。Step 870 is followed by step 875 of selectively cooling the second homogeneous. Preferably, the second homogenate 52 is cooled to ambient temperature or to a suitable storage temperature. Upon completion of steps 870-875, a third filling unit/filling layer is formed. Step 880 includes: combining the cover and the body to complete the manufacture of a capsule having three filling units/fill layers. Step 890 includes discharging the capsule and removing the capsule that is not filled or incompletely filled. That is, the capsule passing through step 880 enters a detecting device such as a weight detecting device in step 890, and when the weight of the capsule is not within the specification, the capsule is automatically excluded; thereby distinguishing the filling completely and not filling Or fill the incomplete capsule and drain the latter two.

因此,本發明之多層填充膠囊以安定性之阻隔層50分隔第一均質物51與第二均質物52,而在較佳實施例中,第一均質物51與第二均質物52為含有藥性之成份。阻隔層50的分隔可防止藥物間的相互影響所造成的溶析特性的變化或交互作用,例如:配方成份因濃度差而互相滲透,因而改變預期的藥效。此外,本發明的多層填充膠囊之製造方法更進一步確保在填充過程中,阻隔層的充填不對第一均質物51或第二均質物52造成另外的影響。Therefore, the multi-layered filled capsule of the present invention separates the first homogeneous substance 51 and the second homogeneous substance 52 by the stability barrier layer 50, and in the preferred embodiment, the first homogeneous substance 51 and the second homogeneous substance 52 are contained in the drug substance. Ingredients. The separation of the barrier layer 50 prevents changes or interactions of the elution characteristics caused by the interaction between the drugs, for example, the formulation components penetrate each other due to the difference in concentration, thereby changing the intended drug effect. Furthermore, the method of manufacturing the multilayer filled capsule of the present invention further ensures that the filling of the barrier layer does not have an additional effect on the first homogeneous substance 51 or the second homogeneous substance 52 during the filling process.

在其他膠囊填充之實施例中,如圖6A-6B所示,亦可先行填充阻隔層50而直接將內部空間分隔為二。此時,不同於上述實施例中,第一均質物及第二均質物皆從同一開口充填。本實施例之膠囊1包含開口4與開口4’,以及分別對應於開口4與開口4’、可分離地與本體2結合之蓋體3及蓋體3’。第一均質物51及第二均質物52則分別由開口4與開口4’填入內部空間;因此本實施例中進行了兩次方向限制步驟。如圖7A-7B所示,步驟910包含:膠囊以蓋體與本體結合的狀態收容於進料斗;步驟920包含:分離至少一蓋體並排除分離不良之膠囊。步驟930包含:充填阻隔層。充填阻隔層之方式可為直接地於內部空間形成與內壁相連的阻隔層,或可先於內部空間安置例如一暫時性支架(未示於圖),再以該支架作為輔助,充填該阻隔層。基本上,本實施例之充填仍須按照上述實施例中之原則,即熔點較高者先行填充;並且,由於本實施例中是先填充阻隔層,因此若第一均質物與第二均質物皆須先加熱以熔解成液體或半固體來填充,則第一均質物與第二均質物的熔點必須小於阻隔層熔點。由於阻隔層組成份中礦物油及石蠟的比例影響阻隔層熔點,因此步驟930進一步包含根據第一均質物與第二均質物之熔點決定阻隔層熔點及礦物油及/或石蠟之比例。此外,同樣地,阻隔層熔點較佳須大於常溫及/或貯存溫度,以避免阻隔層熔化而失去阻隔功能,或者與他層填充物混合。In other embodiments of capsule filling, as shown in Figures 6A-6B, the barrier layer 50 may be filled first to directly divide the interior space into two. At this time, unlike the above embodiment, the first homogeneous substance and the second homogeneous substance are all filled from the same opening. The capsule 1 of the present embodiment includes an opening 4 and an opening 4', and a lid body 3 and a lid body 3' which are detachably coupled to the body 2, respectively, corresponding to the opening 4 and the opening 4'. The first homogeneous substance 51 and the second homogeneous substance 52 are filled into the internal space by the opening 4 and the opening 4', respectively; therefore, the two direction restricting steps are performed in this embodiment. As shown in FIGS. 7A-7B, step 910 includes: the capsule is received in the feeding hopper in a state in which the lid body is coupled to the body; and step 920 includes: separating at least one lid body and removing the capsule having poor separation. Step 930 includes filling the barrier layer. The barrier layer may be filled in such a manner as to directly form a barrier layer connected to the inner wall in the inner space, or may be disposed in front of the inner space, for example, a temporary bracket (not shown), and the bracket is used as an auxiliary to fill the barrier. Floor. Basically, the filling of this embodiment is still required to be filled according to the principle in the above embodiment, that is, the higher melting point is filled first; and, since the barrier layer is filled first in this embodiment, if the first homogeneous substance and the second homogeneous substance are All must be heated to be melted into a liquid or semi-solid to fill, then the melting point of the first homogeneous substance and the second homogeneous substance must be less than the melting point of the barrier layer. Since the ratio of the mineral oil and the paraffin in the barrier layer component affects the melting point of the barrier layer, step 930 further comprises determining the melting point of the barrier layer and the ratio of mineral oil and/or paraffin according to the melting points of the first homogeneous substance and the second homogeneous substance. Further, similarly, the melting point of the barrier layer is preferably greater than normal temperature and/or storage temperature to prevent the barrier layer from melting to lose the barrier function or to be mixed with the layer filler.

步驟935包含:冷卻阻隔層。其中,若步驟930中使用了暫時性支架,該暫時性支架則在步驟935完成時或完成之前自內部空間移除。步驟940包含:進行方向限制。步驟940進行之方向限制為本實施例中第一次方向限制,其使得本體之軸心垂直於水平面,而開口水平朝上,以準備進入下一步驟。步驟950包含:充填第一均質物;步驟955包含:冷卻第一均質物;步驟960包含:結合蓋體與本體並進行方向限制。圖7A接續圖7B。步驟965包含:分離另一蓋體。其中,步驟960中之方向限制為本實施例第二次方向限制,其目的為調整膠囊方向,使得另一蓋體自本體分離後(步驟965),與該另一蓋體相對應之另一開口會朝向例如水平朝上之適當方向以接受填充物。步驟970包含:充填第二均質物;步驟975包含:冷卻第二均質物;步驟980包含:結合另一蓋體與本體。步驟990包含:排出膠囊並排除不填充或填充不完全之膠囊。因此,第一均質物與第二均質物之充填順序除了可按照前述之原則外,本實施例中先行在本體內設置阻隔層的方式提供另一種填充第一均質物與第二均質物的選擇。舉例來說,當第一均質物或第二均質物在填充及常溫/貯存條件下皆為微膠囊、顆粒、粉狀固體、或為半固體、液體時,則此實施例適用於例如:第一均質物為液體、半固體而第二均質物為微膠囊、顆粒、或粉狀固體;或者是第一均質物及第二均質物皆為液體時、或皆為半固體時之充填。因為此方式不需將液體或半固體之阻隔層充填於微膠囊、顆粒、粉狀固體、半固體、或液體表面(施行不易)。另外,前一實施例中,第一均質物為固體而第二均質物為固體、或為半固體、液體之充填亦可以本實施方式施行。Step 935 includes cooling the barrier layer. Wherein, if a temporary bracket is used in step 930, the temporary bracket is removed from the interior space when step 935 is completed or before completion. Step 940 includes: performing a direction restriction. The direction in which step 940 is performed is limited to the first directional restriction in this embodiment, such that the axis of the body is perpendicular to the horizontal plane and the opening is horizontally upwards in preparation for the next step. Step 950 includes: filling the first homogeneous substance; step 955 includes: cooling the first homogeneous substance; and step 960 includes: combining the cover body and the body and performing direction limitation. Figure 7A Continue with Figure 7B . Step 965 includes separating another cover. The direction in step 960 is limited to the second direction limitation of the embodiment, and the purpose is to adjust the direction of the capsule so that another cover body is separated from the body (step 965), and the other cover body is another. The opening will face the appropriate direction, for example horizontally upwards, to accept the filler. Step 970 includes: filling a second homogeneous substance; step 975 includes: cooling the second homogeneous substance; and step 980 includes: combining another cover body and the body. Step 990 includes discharging the capsule and removing the capsule that is not filled or incompletely filled. Therefore, the filling sequence of the first homogeneous substance and the second homogeneous substance may be in accordance with the foregoing principles. In this embodiment, the manner of providing the barrier layer in the body first provides another option of filling the first homogeneous substance and the second homogeneous substance. . For example, when the first homogeneous substance or the second homogeneous substance is microcapsules, granules, powdery solids, or semi-solid, liquid under filling and normal temperature/storage conditions, this embodiment is applicable to, for example: A homogeneous substance is a liquid, a semi-solid and the second homogeneous substance is a microcapsule, a granule, or a powdery solid; or a filling when the first homogeneous substance and the second homogeneous substance are both liquid or both are semi-solid. This method does not require the filling of a liquid or semi-solid barrier layer on microcapsules, granules, powdered solids, semi-solids, or liquid surfaces (not easy to perform). Further, in the first embodiment, the first homogeneous substance is a solid and the second homogeneous substance is a solid or a semi-solid, and the filling of the liquid can also be carried out in the present embodiment.

本發明已由上述相關實施例加以描述,然而上述實施例僅為實施本發明之範例。必需指出的是,已揭露之實施例並未限制本發明之範圍。相反地,包含於申請專利範圍之精神及範圍之修改及均等設置均包含於本發明之範圍內。The present invention has been described by the above-described related embodiments, but the above embodiments are merely examples for implementing the present invention. It must be noted that the disclosed embodiments do not limit the scope of the invention. On the contrary, modifications and equivalents of the spirit and scope of the invention are included in the scope of the invention.

1...膠囊1. . . capsule

2...本體2. . . Ontology

3...蓋體3. . . Cover

3’...蓋體3’. . . Cover

4...開口4. . . Opening

4’...開口4’. . . Opening

5...內部空間5. . . Internal space

50...阻隔層50. . . Barrier layer

51...第一均質物51. . . First homogenate

52...第二均質物52. . . Second homogenate

61...第一分隔空間61. . . First separation space

62...第二分隔空間62. . . Second separation space

7...內壁7. . . Inner wall

810...膠囊以蓋體與本體結合的狀態收容於進料斗810. . . The capsule is housed in the feeding hopper in a state in which the lid body is coupled to the body

820...將由進料斗取出的膠囊進行方向限制820. . . Limit the direction of the capsule taken out of the feed hopper

830...將膠囊之蓋體從本體分離830. . . Separating the cover of the capsule from the body

840...排除分離不良之膠囊及本體有缺陷之膠囊840. . . Excludes poorly isolated capsules and capsules with defective bodies

850...充填第一均質物850. . . Filling the first homogeneous substance

855...冷卻第一均質物855. . . Cooling the first homogeneous substance

860...充填阻隔層860. . . Filling barrier

865...冷卻阻隔層865. . . Cooling barrier

870...充填第二均質物870. . . Filling the second homogeneous substance

875...冷卻第二均質物875. . . Cooling the second homogeneous substance

880...結合蓋體與本體880. . . Combined with cover and body

890...排出膠囊,並排除不填充或填充不完全之膠囊890. . . Discharge the capsule and exclude capsules that are not filled or incompletely filled

910...膠囊以蓋體與本體結合的狀態收容於進料斗910. . . The capsule is housed in the feeding hopper in a state in which the lid body is coupled to the body

920...分離至少一蓋體並排除分離不良之膠囊920. . . Separating at least one cover and removing the poorly separated capsule

930...充填阻隔層930. . . Filling barrier

935...冷卻阻隔層935. . . Cooling barrier

940...進行方向限制940. . . Direction restriction

950...充填第一均質物950. . . Filling the first homogeneous substance

955...冷卻第一均質物955. . . Cooling the first homogeneous substance

960...結合蓋體與本體並進行方向限制960. . . Combine the cover body with the body and restrict the direction

965...分離另一蓋體965. . . Separate another cover

970...充填第二均質物970. . . Filling the second homogeneous substance

975...冷卻第二均質物975. . . Cooling the second homogeneous substance

980...結合另一蓋體與本體980. . . Combine another cover and body

990...排出膠囊並排除不填充或填充不完全之膠囊990. . . Discharge the capsule and exclude capsules that are not filled or incompletely filled

圖1A-1B為本發明與先前技術之膠囊示意圖;1A-1B are schematic views of a capsule of the present invention and prior art;

圖2為本發明多層填充膠囊製造方法之實施例流程圖;2 is a flow chart of an embodiment of a method for manufacturing a multilayer filled capsule of the present invention;

圖3為本發明多層填充膠囊製造方法之實施例示意圖;3 is a schematic view showing an embodiment of a method for manufacturing a multilayer filled capsule of the present invention;

圖4為圖3本發明多層填充膠囊製造方法之簡化之實施例示意圖;Figure 4 is a schematic view showing a simplified embodiment of the method for manufacturing the multilayer filled capsule of the present invention;

圖5為本發明多層填充膠囊製造方法之實施例之局部示意圖;Figure 5 is a partial schematic view showing an embodiment of a method for manufacturing a multilayer filled capsule of the present invention;

圖6A-6B為本發明多層填充膠囊製造方法之另一實施例示意圖;6A-6B are schematic views showing another embodiment of a method for manufacturing a multi-layer filled capsule according to the present invention;

圖7A-7B為圖6A-6B本發明多層填充膠囊製造方法之另一實施例之詳細流程圖。7A-7B are detailed flow diagrams of another embodiment of the method of making a multilayer filled capsule of the present invention of Figs. 6A-6B.

810...膠囊以蓋體與本體結合的狀態收容於進料斗810. . . The capsule is housed in the feeding hopper in a state in which the lid body is coupled to the body

820...將由進料斗取出的膠囊進行方向限制820. . . Limit the direction of the capsule taken out of the feed hopper

830...將膠囊之蓋體從本體分離830. . . Separating the cover of the capsule from the body

840...排除分離不良之膠囊及本體有缺陷之膠囊840. . . Excludes poorly isolated capsules and capsules with defective bodies

850...充填第一均質物850. . . Filling the first homogeneous substance

855...冷卻第一均質物855. . . Cooling the first homogeneous substance

860...充填阻隔層860. . . Filling barrier

865...冷卻阻隔層865. . . Cooling barrier

870...充填第二均質物870. . . Filling the second homogeneous substance

875...冷卻第二均質物875. . . Cooling the second homogeneous substance

880...結合蓋體與本體880. . . Combined with cover and body

890...排出膠囊,並排除不填充或填充不完全之膠囊890. . . Discharge the capsule and exclude capsules that are not filled or incompletely filled

Claims (27)

一種用於膠囊中之一阻隔層,該阻隔層組成份包含重量比值介於0至4之間之礦物油與石蠟,且因應溫度變化產生相變化而使膠囊內部為一個空間或兩個分隔空間。 A barrier layer for use in a capsule comprising a mineral oil and a paraffin having a weight ratio between 0 and 4, and causing a phase change in response to a change in temperature such that the interior of the capsule is a space or two compartments . 一種膠囊,包含:一本體,具有至少一開口及一內部空間;至少一蓋體,可分離地與該本體結合,以封閉該開口;以及一阻隔層,設置於該本體中,且因應溫度變化產生相變化而使膠囊具有該內部空間,或分隔該內部空間為一第一分隔空間及一第二分隔空間;其中該阻隔層組成份包含礦物油與石蠟,且礦物油與石蠟之重量比值介於0至4之間。 A capsule comprising: a body having at least one opening and an inner space; at least one cover detachably coupled to the body to close the opening; and a barrier layer disposed in the body and subject to temperature changes Generating a phase change to cause the capsule to have the internal space, or separating the internal space into a first separation space and a second separation space; wherein the barrier layer component comprises mineral oil and paraffin, and the weight ratio of mineral oil to paraffin is Between 0 and 4. 如申請專利範圍第2項所述之膠囊,其中該膠囊有二個開口及二個蓋體,該二個蓋體係相應於該二個開口,且可分離地與該本體結合,以封閉該二個開口。 The capsule of claim 2, wherein the capsule has two openings and two covers, the two cover systems corresponding to the two openings, and detachably coupled to the body to close the two An opening. 如申請專利範圍第2項所述之膠囊,其中該第一分隔空間含有一第一均質物,該第二分隔空間含有一第二均質物。 The capsule of claim 2, wherein the first compartment contains a first homogeneous substance and the second compartment contains a second homogeneous substance. 如申請專利範圍第4項所述之膠囊,其中該第一均質物或該第二均質物在室溫下之形態為選自固體塊、粉狀固體、顆粒狀固體及微膠囊之固體。 The capsule of claim 4, wherein the first homogeneous substance or the second homogeneous substance is at room temperature in a solid selected from the group consisting of a solid block, a powdery solid, a particulate solid, and a microcapsule. 如申請專利範圍第5項所述之膠囊,其中固體塊之特性係在高於35℃的溫度條件下為液體形態或半固體形態。 The capsule of claim 5, wherein the solid block has a liquid or semi-solid form at a temperature above 35 °C. 如申請專利範圍第6項所述之膠囊,其中該第一均質物或該 第二均質物進一步包含至少一種在高於35℃的溫度條件下為液體形態或半固體形態之熱熔性賦形劑。 The capsule of claim 6, wherein the first homogeneous substance or the capsule The second homogenate further comprises at least one hot melt excipient which is in a liquid or semi-solid form at a temperature above 35 °C. 如申請專利範圍第4項所述之膠囊,其中該第一均質物或該第二均質物在室溫下之形態為液體。 The capsule of claim 4, wherein the first homogeneous substance or the second homogeneous substance is in the form of a liquid at room temperature. 如申請專利範圍第8項所述之膠囊,其中液體包含懸浮液。 The capsule of claim 8 wherein the liquid comprises a suspension. 如申請專利範圍第4項所述之膠囊,其中該第一均質化合物或該第二均質化合物在室溫下之形態為半固體。 The capsule of claim 4, wherein the first homogeneous compound or the second homogeneous compound is semi-solid at room temperature. 如申請專利範圍第6項所述之膠囊,其中該第一均質物之熔點、該阻隔層之熔點、及該第二均質物之熔點間的關係為該第一均質物之熔點大於該阻隔層之熔點,且該阻隔層之熔點大於該第二均質物之熔點。 The capsule of claim 6, wherein a relationship between a melting point of the first homogeneous substance, a melting point of the barrier layer, and a melting point of the second homogeneous substance is a melting point of the first homogeneous substance greater than the barrier layer a melting point, and a melting point of the barrier layer is greater than a melting point of the second homogeneous substance. 如申請專利範圍第6項所述之膠囊,其中該第一均質物之熔點、該阻隔層之熔點、及該第二均質物之熔點間的關係為該阻隔層之熔點大於該第一均質物之熔點及該第二均質物之熔點。 The capsule of claim 6, wherein the relationship between the melting point of the first homogeneous substance, the melting point of the barrier layer, and the melting point of the second homogeneous substance is that the melting point of the barrier layer is greater than the first homogeneous substance. The melting point and the melting point of the second homogeneous substance. 如申請專利範圍第3項所述之膠囊,其中該阻隔層之厚度佔該本體總長的5%至25%。 The capsule of claim 3, wherein the barrier layer has a thickness of from 5% to 25% of the total length of the body. 一種膠囊充填方法,包含下列步驟:提供一膠囊,該膠囊包含一本體及至少一蓋體,該本體包含至少一開口及一內部空間;填充一第一均質物於該內部空間;填充一阻隔層,該阻隔層分隔該內部空間;填充一第二均質物於該內部空間;以及結合該本體與該至少一蓋體;其中該第一均質物與該第二均質物為該阻隔層所隔離,且該 阻隔層組成份包含礦物油與石蠟;礦物油與石蠟之重量比值介於0至4之間。 A capsule filling method comprising the steps of: providing a capsule comprising a body and at least one cover, the body comprising at least one opening and an inner space; filling a first homogeneous substance in the inner space; filling a barrier layer The barrier layer separates the inner space; fills a second homogeneous substance in the inner space; and combines the body with the at least one cover; wherein the first homogeneous substance and the second homogeneous substance are isolated by the barrier layer, And The barrier layer component comprises mineral oil and paraffin wax; the weight ratio of mineral oil to paraffin wax is between 0 and 4. 如申請專利範圍第14項所述之方法,進一步包含對該膠囊進行方向限制,使該本體及該蓋體之軸心垂直於水平面,並使至少一開口水平朝向上方。 The method of claim 14, further comprising limiting the orientation of the capsule such that the axis of the body and the cover are perpendicular to a horizontal plane and the at least one opening is horizontally upward. 如申請專利範圍第14項所述之方法,進一步包含在提供該膠囊步驟之後分離該本體及該蓋體,而暴露該開口。 The method of claim 14, further comprising separating the body and the cover after the step of providing the capsule to expose the opening. 如申請專利範圍第14項所述之方法,其中該第一均質物填充步驟、該阻隔層填充步驟或該第二均質物填充步驟進一步包含加熱該第一均質物、該阻隔層、或該第二均質物,使該第一均質物、該阻隔層或該第二均質物呈現液體或半固體的形態。 The method of claim 14, wherein the first homogenate filling step, the barrier layer filling step or the second homogenate filling step further comprises heating the first homogeneous substance, the barrier layer, or the first The homogenizer is such that the first homogeneous substance, the barrier layer or the second homogeneous substance assumes a liquid or semi-solid form. 如申請專利範圍第17項所述之方法,其中加熱溫度範圍介於25℃與80℃之間。 The method of claim 17, wherein the heating temperature ranges between 25 ° C and 80 ° C. 如申請專利範圍第17項所述之方法,其中該第一均質物填充步驟、該阻隔層填充步驟、該第二均質物填充步驟進一步包含冷卻該第一均質物、該阻隔層、或該第二均質物,使該第一均質物、該阻隔層或該第二均質物呈現固體或半固體的形態。 The method of claim 17, wherein the first homogenate filling step, the barrier layer filling step, and the second homogenate filling step further comprise cooling the first homogeneous substance, the barrier layer, or the first The homogenizer is such that the first homogeneous substance, the barrier layer or the second homogeneous substance assumes a solid or semi-solid form. 如申請專利範圍第14項所述之方法,其中該阻隔層填充步驟包含分隔該內部空間為一第一分隔空間及一第二分隔空間,且該第一分隔空間及該第二分隔空間分別填充有該第一均質物及該第二均質物。 The method of claim 14, wherein the barrier layer filling step comprises separating the internal space into a first separation space and a second separation space, and the first separation space and the second separation space are respectively filled. There is the first homogeneous substance and the second homogeneous substance. 如申請專利範圍第14項所述之方法,進一步包含確認該膠囊是否有缺陷。 The method of claim 14, further comprising confirming whether the capsule is defective. 如申請專利範圍第14項所述之方法,進一步包含排出結合 完畢之該膠囊。 The method of claim 14, further comprising discharging the combination The capsule is finished. 如申請專利範圍第22項所述之方法,其中排出結合完畢之該膠囊之步驟進一步包含排除不填充或填充不完全之該膠囊。 The method of claim 22, wherein the step of expelling the bonded capsule further comprises excluding the capsule that is not filled or incompletely filled. 如申請專利範圍第14項所述之方法,其中該阻隔層之厚度佔該本體總長的5%至25%。 The method of claim 14, wherein the barrier layer has a thickness of from 5% to 25% of the total length of the body. 如申請專利範圍第14項所述之方法,其中該阻隔層填充步驟進一步包含噴灑該阻隔層於該內壁之一釋出點使該阻隔層形成於該第一均質物表面,且該釋出點與該第一均質物頂部之間的距離為2mm至3mm之間。 The method of claim 14, wherein the barrier layer filling step further comprises spraying the barrier layer at a release point of the inner wall to form the barrier layer on the first homogeneous surface, and the releasing The distance between the point and the top of the first homogenizer is between 2 mm and 3 mm. 如申請專利範圍第25項所述之方法,其中該阻隔層噴灑步驟中,一噴灑點與該釋出點所連成之一噴灑線與該內壁徑向之間的夾角度數範圍為10°與40°之間。 The method of claim 25, wherein in the step of spraying the barrier layer, the angle between the spray line and the radial direction of the spray line and the release point is in the range of 10 Between ° and 40 °. 如申請專利範圍第19項所述之方法,其中該第一均質物填充步驟、該阻隔層填充步驟或該第二均質物填充步驟之間的填充順序係由該第一均質物質、該阻隔層及該第二均質物之熔點較高者先行填充。The method of claim 19, wherein the filling sequence between the first homogenate filling step, the barrier layer filling step or the second homogenate filling step is the first homogeneous substance, the barrier layer And the higher melting point of the second homogeneous substance is filled first.
TW99144189A 2009-12-16 2010-12-16 Barrier for capsule, capsule using the same, and method of filling capsule TWI426897B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW99144189A TWI426897B (en) 2009-12-16 2010-12-16 Barrier for capsule, capsule using the same, and method of filling capsule

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TW98143234 2009-12-16
TW99144189A TWI426897B (en) 2009-12-16 2010-12-16 Barrier for capsule, capsule using the same, and method of filling capsule

Publications (2)

Publication Number Publication Date
TW201121538A TW201121538A (en) 2011-07-01
TWI426897B true TWI426897B (en) 2014-02-21

Family

ID=45045648

Family Applications (1)

Application Number Title Priority Date Filing Date
TW99144189A TWI426897B (en) 2009-12-16 2010-12-16 Barrier for capsule, capsule using the same, and method of filling capsule

Country Status (1)

Country Link
TW (1) TWI426897B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4738724A (en) * 1983-11-04 1988-04-19 Warner-Lambert Company Method for forming pharmaceutical capsules from starch compositions
US5443461A (en) * 1993-08-31 1995-08-22 Alza Corporation Segmented device for simultaneous delivery of multiple beneficial agents
US20080219803A1 (en) * 2005-11-30 2008-09-11 Werner Runft Weighing Device for a Packaging Machine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4738724A (en) * 1983-11-04 1988-04-19 Warner-Lambert Company Method for forming pharmaceutical capsules from starch compositions
US5443461A (en) * 1993-08-31 1995-08-22 Alza Corporation Segmented device for simultaneous delivery of multiple beneficial agents
US20080219803A1 (en) * 2005-11-30 2008-09-11 Werner Runft Weighing Device for a Packaging Machine

Also Published As

Publication number Publication date
TW201121538A (en) 2011-07-01

Similar Documents

Publication Publication Date Title
ES2257412T3 (en) ENCAPSULATION OF A TOXIC NUCLEUS IN A NON-TOXIC REGION IN AN ORAL DOSAGE FORM.
ES2316791T3 (en) DOSAGE FORM CONTROLLED BY DIFFUSION AND MANUFACTURING METHOD INCLUSIVE THREE-DIMENSIONAL PRINTING.
JP2020506918A (en) Controlled release dosage forms at specific gastrointestinal sites
JP2023533478A (en) Rapidly dispersible tablet with internal cavity
Melocchi et al. Lego-inspired capsular devices for the development of personalized dietary supplements: Proof of concept with multimodal release of caffeine
JP2021535199A (en) Manufacturing method of solid product
Jawahar et al. Multi unit particulates systems (MUPS): a novel pellets for oral dosage forms
TW202207905A (en) Rapidly-orodispersible tablets having an interior cavity
Aulton Powders, granules and granulation
Nakamura et al. Preparation of controlled-release fine particles using a dry coating method
Tidau et al. Modified release kinetics in dual filament 3D printed individualized oral dosage forms
TWI426897B (en) Barrier for capsule, capsule using the same, and method of filling capsule
JP6878417B2 (en) Dosage forms and their use
US20160228332A1 (en) Multi-layer capsule and manufacture method thereof
JP5622185B2 (en) High content soft capsule and method for producing the same
JP7319956B2 (en) Granulation composition
JP6195280B2 (en) Multilayer capsule and method for producing the same
Rowley Filling of liquids and semi-solids into hard two-piece capsules
AU2011371241B2 (en) Multi-layer capsule and manufacture method thereof
Katsiotis et al. Combinatorial 3D printed dosage forms for a two-step and controlled drug release
Sivert et al. Strategies for Modified Release Oral Formulation Development
Tserkovnaya et al. Polypill as a Personalized Dosage Form: Production Technology
Sen et al. History and Present Scenario of Additive Manufacturing in Pharmaceuticals
Akhter et al. A two pulse drug delivery system for amoxicillin: An attempt to counter the scourge of bacterial resistance against antibiotics
YADAV et al. Indian Journal of Novel Drug Delivery